Market Overview

Global Cancer Immunotherapy Market size was valued at USD 126.84 Billion in 2023 and is poised to grow from USD 138.19 Billion in 2024 to USD 274.35 Billion by 2032, growing at a CAGR of 8.95% in the forecast period (2024-2032).

The Global Market for Cancer Immunotherapy is a transformer for cancer treatment as it uses the body's immune system to fight cancer. Immunotherapy is restoring the immune system's defenses, which provides a accurate and perhaps less harmful alternative to therapies like radiation. Adoptive cell therapies such as CAR T-cell therapy, monoclonal antibodies, immune checkpoint inhibitors, and cancer vaccines all part of this novel treatment ideal aim to target processes of tumor development and survival.

The capacity of immunotherapy to provide long-lasting effects, especially in cases of advanced or metastatic malignancies, is a benefit. Numerous immunotherapies have revealed the ability to "train" the immune system to realize cancer cells, providing long-term survival protection. medicines that target immune checkpoints like PD-1, PD-L1, and CTLA-4 have made this clear. The way that tumors like melanoma, non-small cell lung cancer, and renal cell carcinoma have been changed by these medicines is handled.

The market is being driven by the increasing use of combination treatments. In overcoming resistance, increased power has been indicated by immunotherapies and developing clinical outcomes when combined with other new drugs or traditional therapies. Developments in genetic engineering and biotechnology have made it easier to create specialized immunotherapies, which match treatment modalities with patient profiles. This precision medicine strategy increases immunotherapy's attractiveness by reducing side effects.

Obstacles, including development costs, are besetting its likely, the market for cancer immunotherapy, complex manufacturing procedures, and problems with accessibility, especially in low- and middle-income nations. Managing immune-related adverse effects is still a therapeutic goal since not all patients respond to immunotherapy.

Key Findings:

As per W.H.O. report:

• Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths.
• The most common cancers are breast, lung, colon and rectum and prostate cancers.
• Around one-third of deaths from cancer are due to tobacco use, high body mass index, alcohol consumption, low fruit and vegetable intake, and lack of physical activity. In addition, air pollution is an important risk factor for lung cancer.
• Cancer-causing infections, such as human papillomavirus (HPV) and hepatitis, are responsible for approximately 30% of cancer cases in low- and lower-middle-income countries.
• Many cancers can be cured if detected early and treated effectively.
• The most common causes of cancer death in 2020 were:
• lung (1.80 million deaths)
• colon and rectum (916 000 deaths)
• liver (830 000 deaths)
• stomach (769 000 deaths) and
• breast (685 000 deaths).

Market Drivers

Rising Adoption of Combination Therapies

• The growing use of medications in cancer immunotherapy, the oncology landscape is being swap, which makes better treatment results. Using two or more treatment modalities to more effectively target cancer is known as combination therapy. In the context of immunotherapy, these combinations might require immune checkpoint obstacle in coincidence with newer medicines like cancer vaccines or targeted therapies. This strategy looks for to boost the immune system, get beyond resistance mechanisms, and effectiveness.
• Stunning Results in treating some types of cancer have been shown by immune inhibitors, but not all patients take advantage of these therapies. When combined with other modalities, they can alter the tumor microenvironment, increasing the range of tumors that can be treated and making the tumor more vulnerable to immune response. Cancer care as research continues to recognized mechanisms of action has been individualized by combination medicines that have become a key component and biomarkers for therapy optimization.

Key Findings:

• In October 2022, AstraZeneca’s Imjudo (tremelimumab) in combination with Imfinzi (durvalumab) has been approved in the US for the treatment of adult patients with unresectable hepatocellular carcinoma (HCC), the most common type of liver cancer. The novel dose and schedule of the combination, which includes a single dose of the anti-CTLA-4 antibody Imjudo 300mg added to the anti-PD-L1 antibody Imfinzi 1500mg followed by Imfinzi every four weeks, is called the STRIDE regimen (Single Tremelimumab Regular Interval Durvalumab).

Growing Focus on Precision Medicine and Personalized Treatments

• Treatments to each patient's distinct genetic, genomic, and immunological feature, the increasing emphasis on clarity medicine and individualized medicines is changing cancer immunotherapy. By using this approach, doctors may choose the best medicines, reduce side effects.
• The Options for customized immunotherapy, such cancer vaccines and CAR T-cell treatment, are prime examples of this plan as they are made to specifically target each patient's particular tumor antigen. Furthermore, in order to determine which patients are most likely to benefit from immune checkpoint inhibitors which modulate the immune response biomarker-driven decisions, such as PD-L1 expression levels or tumor mutational load, are increasingly being used.
• Precision medicine avoids useless therapies, which maximizes healthcare resources while also improving therapeutic efficacy. Also, the capacity to customize therapies in real-time is being pushed by continuous improvements in diagnostic technologies, such as liquid biopsies and next-generation sequencing. The focus on precision medicine keeps growing as our understanding of tumor immune interactions grows, innovation and changing the way cancer care is provided in the future.

Market Opportunities

Integration of Artificial Intelligence in Drug Discovery and Patient Selection

• The use of artificial intelligence (AI) in patient selection and medication development is greatly growing cancer immunotherapy, which increases accuracy, smooths research and improves treatment results. In addition to cutting expenses and speeding up the development process, this enables researchers to find new immunotherapy mechanisms that could have gone ignored with more conventional approaches.AI algorithms in drug development to find possible therapeutic targets examine large-scale genomic, proteomic, and chemical library datasets and make timely predictions about the effectiveness of novel drug candidates.
• The AI is used in patient selection to better stratify patients by utilizing information from biomarker profiles, diagnostic imaging, and electronic health records.In addition to improving treatment effectiveness, this accuracy reduces unnecessary exposure to potentially harmful or ineffective treatments. Based on the immune profile and tumor features, AI assists in matching patients to the best immunotherapy by finding certain genetic or molecular markers.

Market Restraining Factors

Adverse Immune-Related Side Effects

• The activation and overstimulation of the immune system result in immune related side effects, which pose a serious problem in cancer immunotherapy. Pneumonitis, colitis, and hepatitis are just a few of the serious problems that can result from these side effects, which can gastrointestinal tract, impact the skin, endocrine glands, lungs, and liver. Immune-related adverse events (irAEs) are unpleasant that can occur when raised immune activity backfires and causes the immune system to attack healthy tissues and organs.
• Checkpoint inhibitors, including as anti-PD-1/PD-L1 and anti-CTLA-4 antibodies, are particularly associated with these unpleasant side effects due to their mechanism of action, which disrupts immunological self-tolerance. Managing irAEs requires striking a challenging balance between preventing detrimental immune responses.

Segmentation Analysis

The market scope is segmented because of by Product, by Application, by End Use, by Distribution Channel.

By Product

Based on the Product of the market is segmented into Monoclonal Antibodies, Immunomodulators, Oncolytic Viral Therapies & Cancer Vaccines.

The cancer immunotherapy market's product divisions, because of their effectiveness, adaptability, and extensive use in oncology, have been dominated by monoclonal antibodies, or mAbs. Because these proteins are tailored to selectively target antigens expressed on cancer cells, they are very successful at treating a variety of cancers while causing the least amount of harm to healthy organs. Immune checkpoint inhibitors, like pembrolizumab (Keytruda) and nivolumab (Opdivo), which target PD-1/PD-L1 pathways to unleash the immune system against tumors, are among the most effective immunotherapy medications. Broad match across a variety of cancer types, including melanoma, lung, breast, and colorectal cancers, has assign to the market initiative of monoclonal antibodies. The potential of next-generation antibodies, including bispecific antibodies and antibody-drug conjugates, is constantly being expanded, making a component of cancer immunotherapy. They also increase their therapeutic versatility by serving as both stand-alone treatments and elements of combination regimens, which increases their efficacy and reach.

By Application

Based on the Application of the market is segmented into Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Head & Neck Cancer, Ovarian Cancer, Pancreatic Cancer, Others.

Lung cancer has been the most leading application area in the market for cancer immunotherapy. This is because lung cancer is one of the most common and fatal malignancies, with a significant frequency all over the world. Since lung cancer, especially non-small cell lung cancer (NSCLC), frequently exhibits late-stage symptoms that make it more difficult to treat with conventional techniques like chemotherapy and radiation, immunotherapy research.

Lung cancer's market domination in immunotherapy is further motivated by notable developments in immune checkpoint inhibitors, such nivolumab (Opdivo) and pembrolizumab (Keytruda), which have shown effectiveness in treating advanced and metastatic non-small cell lung cancer. By focusing on the PD-1/PD-L1 pathway, these treatments have changed the way lung cancer is treated, providing patients with alternatives in the past with long-lasting effects and increased survival rates.

Regional Snapshots

Geographically, the report gives information on markets in Latin America, Asia-Pacific, Europe, North America, and MEA. The market for cancer immunotherapy has been dominated by North America, mainly because of its healthcare system, significant spending in R&D, and acceptance of innovative medical technology. With so many biotechnology and pharmaceutical businesses, the United States is a significant driver in the development of cancer. The U.S. Food and Drug Administration's (FDA) approval of treatments, especially immune checkpoint inhibitors, has built up the market in this area. Furthermore, North America has a big patient base, a strong healthcare system, and a well-established structure, all of which support the broad use of cutting-edge cancer therapies.

However, the cancer immunotherapy market is expected to develop at the fastest rate in the Asia-Pacific region. The increased prevalence of cancer, advancements in healthcare facilities, and growing government programs to use of cutting-edge cancer therapies are some of the causes behind this quick expansion. Significant advancements are being made in the creation and marketing of immunotherapies by nations like China and Japan. The demand for immunotherapy is also anticipated to rise in Asia-Pacific, making it the area with the fastest rate of growth in the next years due to factors including rising incomes, improved access to healthcare, and more knowledge of cancer treatment choices. Innovative cures are becoming more accessible in the region as a result of an increase in clinical trials and partnerships between regional businesses and international pharmaceutical corporations.

List of Companies Profiled

• Pfizer Inc.
• AstraZeneca
• Merck & Co., Inc
• Hoffmann-La Roche Ltd
• Bristol-Myers Squibb Company
• Novartis AG
• Lilly
• Johnson & Johnson Services, Inc
• Immunocore, Ltd

Key Industry Developments

• The MEKTOVI (binimetinib) + BRAFTOVI (encorafenib) combination was introduced by Pfizer in October 2023 to treat adult patients with metastatic non-small cell lung cancer (NSCLC) who have a BRAF V600E mutation, as identified by an FDA-approved test.
• The U.S. Food and Drug Administration (FDA) authorized Merck's anti-PD-1 medication KEYTRUDA in October 2023 for use as a neoadjuvant and adjuvant treatment after surgery in patients with resectable non-small cell lung cancer (NSCLC).
• The U.S. FDA authorized Takeda's FRUZAQLA (fruquintinib) for previously treated metastatic colorectal cancer in December 2023.

Report Coverage

The report will cover the qualitative and quantitative data on the Global Cancer Immunotherapy Market. The qualitative data includes latest trends, market players analysis, market drivers, market opportunity, and many others. Also, the report quantitative data includes market size for every region, country, and segments according to your requirements. We can also provide customize report in every industry vertical.

Report Scope and Segmentations

Global Cancer Immunotherapy Market Regional Analysis

North America accounted for the highest xx% market share in terms of revenue in the Cancer Immunotherapy market and is expected to expand at a CAGR of xx% during the forecast period. This growth can be attributed to the growing adoption of Cancer Immunotherapy. The market in APAC is expected to witness significant growth and is expected to register a CAGR of xx% over upcoming years, because of the presence of key Cancer Immunotherapy companies in economies such as Japan and China.

The objective of the report is to present comprehensive analysis of Global Cancer Immunotherapy Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language.

Cancer Immunotherapy Market Report is also available for below Regions and Country Please Ask for that

North America

• U.S.
• Canada

Europe

• Switzerland
• Belgium
• Germany
• France
• U.K.
• Italy
• Spain
• Sweden
• Netherland
• Turkey
• Rest of Europe

Asia-Pacific

• India
• Australia
• Philippines
• Singapore
• South Korea
• Japan
• China
• Malaysia
• Thailand
• Indonesia
• Rest Of APAC

Latin America

• Mexico
• Argentina
• Peru
• Colombia
• Brazil
• Rest of South America

Middle East and Africa

• Saudi Arabia
• UAE
• Egypt
• South Africa
• Rest Of MEA

Points Covered in the Report

• The points that are discussed within the report are the major market players that are involved in the market such as market players, raw material suppliers, equipment suppliers, end users, traders, distributors and etc.
• The complete profile of the companies is mentioned. And the capacity, production, price, revenue, cost, gross, gross margin, sales volume, sales revenue, consumption, growth rate, import, export, supply, future strategies, and the technological developments that they are making are also included within the report. This report analysed 12 years data history and forecast.
• The growth factors of the market are discussed in detail wherein the different end users of the market are explained in detail.
• Data and information by market player, by region, by type, by application and etc., and custom research can be added according to specific requirements.
• The report contains the SWOT analysis of the market. Finally, the report contains the conclusion part where the opinions of the industrial experts are included.

Key Reasons to Purchase

• To gain insightful analyses of the Cancer Immunotherapy market and have comprehensive understanding of the global market and its commercial landscape.
• Assess the production processes, major issues, and solutions to mitigate the development risk.
• To understand the most affecting driving and restraining forces in the market and its impact in the global market.
• Learn about the Cancer Immunotherapy market strategies that are being adopted by leading respective organizations.
• To understand the future outlook and prospects for the Cancer Immunotherapy market. Besides the standard structure reports, we also provide custom research according to specific requirements.

Research Scope of Cancer Immunotherapy Market

• Historic year: 2015- 2019
• Base year: 2020
• Forecast: 2021 to 2028
• Representation of Market revenue in USD Million

Cancer Immunotherapy Market Trends: Market key trends which include Increased Competition and Continuous Innovations Trends: